UNLABELLED: The Genomic Medicine Model aims to facilitate patient engagement, patient/provider education of genomics/personalized medicine, and uptake of risk-stratified evidence-based prevention guidelines using MeTree, a patient-facing family health history (FHH) collection and clinical decision support (CDS) program. Here we report the number of increased risk (above population-level risk) patients identified for breast/ovarian cancer, colon cancer, hereditary syndrome risk, and thrombosis; the prevalence of FHH elements triggering increased-risk status; and the resources needed to manage their risk. STUDY DESIGN: hybrid implementation-effectiveness study of adults with upcoming well-visits in 2 primary care practices in Greensboro, NC. PARTICIPANTS: 1,184, mean age = 58.8, female = 58% (N = 694), non-white = 20% (N = 215). Increased Risk: 44% (N = 523). RECOMMENDATIONS: genetic counseling = 26% (N = 308), breast MRI = 0.8% (N = 10), breast chemoprophylaxis = 5% (N = 58), early/frequent colonoscopies = 19% (N = 221), ovarian cancer screening referral = 1% (N = 14), thrombosis testing/counseling = 2.4% (N = 71). FHH elements: 8 FHH elements lead to 37.3% of the increased risk categorizations (by frequency): first-degree-relative (FDR) with polyps age ≥60 (7.1%, N = 85), three relatives with Lynch-related cancers (5.4%, N = 65), FDR with polyps age <60 (5.1%, N = 61), three relatives on same side of family with same cancer (4.9%, N = 59), Gail score ≥1.66% (4.9%, N = 58), two relatives with breast cancer (one ≤age 50) (4.1%, N = 49), one relative with breast cancer ≤age 40 (4.1%, N = 48), FDR with colon cancer age ≥60 (1.7%, N = 20). MeTree identifies a high percentage of individuals in the general primary care population needing non-routine risk management/prevention for the selected conditions. Implementing risk-stratification in primary care will likely increase demand for related-resources, particularly colon screening and GC. Understanding the prevalence of FHH elements helps predict resource needs and may aid in guideline development.
UNLABELLED: The Genomic Medicine Model aims to facilitate patient engagement, patient/provider education of genomics/personalized medicine, and uptake of risk-stratified evidence-based prevention guidelines using MeTree, a patient-facing family health history (FHH) collection and clinical decision support (CDS) program. Here we report the number of increased risk (above population-level risk) patients identified for breast/ovarian cancer, colon cancer, hereditary syndrome risk, and thrombosis; the prevalence of FHH elements triggering increased-risk status; and the resources needed to manage their risk. STUDY DESIGN: hybrid implementation-effectiveness study of adults with upcoming well-visits in 2 primary care practices in Greensboro, NC. PARTICIPANTS: 1,184, mean age = 58.8, female = 58% (N = 694), non-white = 20% (N = 215). Increased Risk: 44% (N = 523). RECOMMENDATIONS: genetic counseling = 26% (N = 308), breast MRI = 0.8% (N = 10), breast chemoprophylaxis = 5% (N = 58), early/frequent colonoscopies = 19% (N = 221), ovarian cancer screening referral = 1% (N = 14), thrombosis testing/counseling = 2.4% (N = 71). FHH elements: 8 FHH elements lead to 37.3% of the increased risk categorizations (by frequency): first-degree-relative (FDR) with polyps age ≥60 (7.1%, N = 85), three relatives with Lynch-related cancers (5.4%, N = 65), FDR with polyps age <60 (5.1%, N = 61), three relatives on same side of family with same cancer (4.9%, N = 59), Gail score ≥1.66% (4.9%, N = 58), two relatives with breast cancer (one ≤age 50) (4.1%, N = 49), one relative with breast cancer ≤age 40 (4.1%, N = 48), FDR with colon cancer age ≥60 (1.7%, N = 20). MeTree identifies a high percentage of individuals in the general primary care population needing non-routine risk management/prevention for the selected conditions. Implementing risk-stratification in primary care will likely increase demand for related-resources, particularly colon screening and GC. Understanding the prevalence of FHH elements helps predict resource needs and may aid in guideline development.
Authors: Kristin B Niendorf; Melissa A Geller; Rachel Isaksson Vogel; Timothy R Church; Anna Leininger; Angela Bakke; Robert D Madoff Journal: Fam Cancer Date: 2016-10 Impact factor: 2.375
Authors: Jennifer S Haas; Heather J Baer; Katyuska Eibensteiner; Elissa V Klinger; Stella St Hubert; George Getty; Phyllis Brawarsky; E John Orav; Tracy Onega; Anna N A Tosteson; David W Bates; Graham Colditz Journal: Am J Prev Med Date: 2016-09-14 Impact factor: 5.043
Authors: Elizabeth S Chen; Elizabeth W Carter; Tamara J Winden; Indra Neil Sarkar; Yan Wang; Genevieve B Melton Journal: J Am Med Inform Assoc Date: 2014-10-21 Impact factor: 4.497
Authors: June C Carroll; Denise Campbell-Scherer; Joanne A Permaul; Jesse Myers; Donna P Manca; Christopher Meaney; Rahim Moineddin; Eva Grunfeld Journal: Can Fam Physician Date: 2017-01 Impact factor: 3.275
Authors: R Ryanne Wu; Rachel A Myers; Adam H Buchanan; David Dimmock; Kimberly G Fulda; Irina V Haller; Susanne B Haga; Melissa L Harry; Catherine McCarty; Joan Neuner; Teji Rakhra-Burris; Nina Sperber; Corrine I Voils; Geoffrey S Ginsburg; Lori A Orlando Journal: Appl Clin Inform Date: 2019-03-13 Impact factor: 2.342
Authors: Lori A Orlando; R Ryanne Wu; Rachel A Myers; Adam H Buchanan; Vincent C Henrich; Elizabeth R Hauser; Geoffrey S Ginsburg Journal: Genet Med Date: 2016-03-03 Impact factor: 8.822